CalciMedica (CALC) Common Equity (2019 - 2026)
CalciMedica's (CALC) quarterly Common Equity came in at -$1.1 million in Q1 2026, down 110.14% YoY from $10.9 million in Q1 2025, and up 83.38% on a QoQ basis from -$6.6 million in Q4 2025.
CalciMedica (CALC) Common Equity (2019 - 2026) Analysis & Trends
CalciMedica (CALC) has 8 years of Common Equity data on file, last reported at -$1.1 million in Q1 2026.
- Quarterly Common Equity fell 110.14% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.1 million (down 110.14% YoY) and the FY2025 annual result came in at -$6.6 million, down 146.09% from the prior year.
- Common Equity advanced to -$1.1 million in Q1 2026, from -$6.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $22.0 million in Q1 2023 to a low of -$71.8 million in Q3 2022.
- A 5-year average of -$9.3 million and a median of $8.2 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity tumbled 199.52% — and 2023, when it jumped 132.73%.
- Tracing CALC's Common Equity over 5 years: stood at -$71.3 million in 2022, then soared by 111.44% to $8.2 million in 2023, then jumped by 76.66% to $14.4 million in 2024, then plunged by 146.09% to -$6.6 million in 2025, then soared by 83.38% to -$1.1 million in 2026.
- The last three Common Equity figures came in at -$1.1 million (Q1 2026), -$6.6 million (Q4 2025), and -$268000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | CalciMedica | 9.80 Mn | -8.82 Mn | - | 5.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.51 Mn |
| Mar 31, 2026 | -1.10 Mn |
| Dec 31, 2025 | -6.64 Mn |
| Sep 30, 2025 | -268,000.00 |
| Jun 30, 2025 | 6.10 Mn |
| Mar 31, 2025 | 10.89 Mn |
| Dec 31, 2024 | 14.41 Mn |
| Sep 30, 2024 | 9.03 Mn |
| Jun 30, 2024 | 13.84 Mn |
| Mar 31, 2024 | 17.25 Mn |
| Dec 31, 2023 | 8.16 Mn |
| Sep 30, 2023 | 12.16 Mn |
| Jun 30, 2023 | 16.22 Mn |
| Mar 31, 2023 | 22.02 Mn |
| Dec 31, 2022 | -71.30 Mn |
| Sep 30, 2022 | -71.79 Mn |
| Jun 30, 2022 | -69.97 Mn |
| Mar 31, 2022 | -67.28 Mn |
| Dec 31, 2021 | -63.99 Mn |
| Sep 30, 2021 | 72.14 Mn |